Scandinavian Real Heart (HEART.ST) Stock Analysis & AI Equity Report
Scandinavian Real Heart (HEART.ST) overview
Scandinavian Real Heart (HEART.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Scandinavian Real Heart reported revenue of SEK 0m and operating profit of SEK -15.3m; the year-end share price was 13.85 SEK and market capitalisation was SEK 69.5m. Scandinavian Real Heart is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Scandinavian Real Heart's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Scandinavian Real Heart
Scandinavian Real Heart AB develops Realheart TAH, a total artificial heart designed to mimic the shape, function and blood flow of the human heart. The company is advancing the device through preclinical testing and regulatory preparation, while building patent protection around its core technology. Its value driver is future commercialization for patients with severe heart failure.
Generate the Scandinavian Real Heart report
Scandinavian Real Heart is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Scandinavian Real Heart and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.